Last reviewed · How we verify
GC3102C
GC3102C is a small molecule that targets the SGLT2 receptor.
GC3102C is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes, Chronic kidney disease.
At a glance
| Generic name | GC3102C |
|---|---|
| Sponsor | Green Cross Corporation |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Biologic |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
GC3102C works by inhibiting the sodium-glucose cotransporter 2 (SGLT2) in the kidneys, reducing glucose reabsorption and lowering blood glucose levels. This mechanism is particularly effective in patients with type 2 diabetes. By reducing glucose reabsorption, GC3102C also has a mild diuretic effect, which can help reduce blood pressure.
Approved indications
- Type 2 diabetes
- Chronic kidney disease
Common side effects
- Nausea
- Diarrhea
- Vomiting
- Hypotension
- Increased urination
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GC3102C CI brief — competitive landscape report
- GC3102C updates RSS · CI watch RSS
- Green Cross Corporation portfolio CI